Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G S Steele

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Urology|October 23, 1997
Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followupG S Steele, D J Sleep
Oncology (Williston Park, N.Y.)|May 1, 1997
Current role of retroperitoneal lymph node dissection in testicular cancerG S Steele, J P Richie
Comprehensive Therapy|September 14, 2000
Management of low-stage nonseminomatous germ cell tumors of the testisG S Steele, J P Richie
Urology|December 31, 1997
Transitional cell carcinoma of the fossa navicularisG S Steele, J R Fielding, A Renshaw, et al.
Archives of Pathology & Laboratory Medicine|November 1, 1994
Advanced prostate cancer with normal serum prostate-specific antigen valuesR J Cohen, Z Haffejee, G S Steele, et al.
Cancer|November 26, 1999
The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996G S Steele, J P Richie, A K Stewart, et al.
The Journal of Urology|July 14, 2000
Combination of symptom score, flow rate and prostate volume for predicting bladder outflow obstruction in men with lower urinary tract symptomsG S Steele, M P Sullivan, D J Sleep, et al.
The Journal of Urology|July 29, 1998
Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptomsK Ameda, G S Steele, M P Sullivan, et al.
The Journal of Urology|October 22, 2011
Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancerS B Williams, R Kacker, D Winston, et al.
Urologic Oncology|June 24, 2021
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancerK Montazeri, G Dranitsaris, J D Thomas, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Urology|October 23, 1997
Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followupG S Steele, D J Sleep
Oncology (Williston Park, N.Y.)|May 1, 1997
Current role of retroperitoneal lymph node dissection in testicular cancerG S Steele, J P Richie
Comprehensive Therapy|September 14, 2000
Management of low-stage nonseminomatous germ cell tumors of the testisG S Steele, J P Richie
Urology|December 31, 1997
Transitional cell carcinoma of the fossa navicularisG S Steele, J R Fielding, A Renshaw, et al.
Archives of Pathology & Laboratory Medicine|November 1, 1994
Advanced prostate cancer with normal serum prostate-specific antigen valuesR J Cohen, Z Haffejee, G S Steele, et al.
Cancer|November 26, 1999
The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996G S Steele, J P Richie, A K Stewart, et al.
The Journal of Urology|July 14, 2000
Combination of symptom score, flow rate and prostate volume for predicting bladder outflow obstruction in men with lower urinary tract symptomsG S Steele, M P Sullivan, D J Sleep, et al.
The Journal of Urology|July 29, 1998
Detrusor contraction duration as a urodynamic parameter of bladder outlet obstruction for evaluating men with lower urinary tract symptomsK Ameda, G S Steele, M P Sullivan, et al.
The Journal of Urology|October 22, 2011
Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancerS B Williams, R Kacker, D Winston, et al.
Urologic Oncology|June 24, 2021
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancerK Montazeri, G Dranitsaris, J D Thomas, et al.
Pageof 1